Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 2
1956 2
1957 1
1958 1
1959 1
1962 1
1964 2
1969 2
1972 2
1979 1
1983 1
1986 1
1987 3
1989 2
1991 3
1992 2
1993 1
1994 2
1995 5
1997 1
1998 1
2000 1
2002 1
2003 1
2004 1
2006 2
2007 2
2008 1
2009 2
2010 5
2012 3
2013 3
2014 3
2015 1
2016 4
2017 5
2018 9
2019 5
2020 9
2021 13
2022 15
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Paz-Ares L, et al. Among authors: de marchi p. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476593 Clinical Trial.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Reck M, et al. Among authors: de marchi p. ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1. ESMO Open. 2021. PMID: 34607285 Free PMC article. Clinical Trial.
Lung cancer in Brazil.
Araujo LH, Baldotto C, Castro G Jr, Katz A, Ferreira CG, Mathias C, Mascarenhas E, Lopes GL, Carvalho H, Tabacof J, Martínez-Mesa J, Viana LS, Cruz MS, Zukin M, Marchi P, Terra RM, Ribeiro RA, Lima VCC, Werutsky G, Barrios CH; Grupo Brasileiro de Oncologia Torácica. Araujo LH, et al. Among authors: marchi p. J Bras Pneumol. 2018 Jan-Feb;44(1):55-64. doi: 10.1590/S1806-37562017000000135. J Bras Pneumol. 2018. PMID: 29538545 Free PMC article. Review.
Obesity, inflammation, and cancer in dogs: Review and perspectives.
Marchi PH, Vendramini THA, Perini MP, Zafalon RVA, Amaral AR, Ochamotto VA, Da Silveira JC, Dagli MLZ, Brunetto MA. Marchi PH, et al. Front Vet Sci. 2022 Oct 3;9:1004122. doi: 10.3389/fvets.2022.1004122. eCollection 2022. Front Vet Sci. 2022. PMID: 36262532 Free PMC article. Review.
Dealing with lung cancer in the COVID-19 scenario (A review).
Aran V, De Marchi P, Zamboni M, Ferreira CG. Aran V, et al. Among authors: de marchi p. Mol Clin Oncol. 2021 Feb;14(2):27. doi: 10.3892/mco.2020.2189. Epub 2020 Dec 14. Mol Clin Oncol. 2021. PMID: 33414908 Free PMC article. Review.
Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors.
Petaccia de Macedo M, Toledo Nascimento EC, Soares FA, Costa Santini F, D'Almeida Costa F, Werneck da Cunha I, Ramella Munhoz R, De Marchi P, Carnier Jorge TW, Ramos Moreira Leite K. Petaccia de Macedo M, et al. Among authors: de marchi p. Clin Pathol. 2023 Sep 15;16:2632010X231197080. doi: 10.1177/2632010X231197080. eCollection 2023 Jan-Dec. Clin Pathol. 2023. PMID: 37719804 Free PMC article. Review.
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
Garon EB, Lu S, Goto Y, De Marchi P, Paz-Ares L, Spigel DR, Thomas M, Yang JC, Ardizzoni A, Barlesi F, Orlov S, Yoshioka H, Mountzios G, Khanna S, Bossen C, Carbini M, Turri S, Myers A, Cho BC. Garon EB, et al. Among authors: de marchi p. J Clin Oncol. 2024 Jan 10;42(2):180-191. doi: 10.1200/JCO.23.00910. Epub 2023 Oct 3. J Clin Oncol. 2024. PMID: 37788412 Clinical Trial.
SMN-deficient cells exhibit increased ribosomal DNA damage.
Karyka E, Berrueta Ramirez N, Webster CP, Marchi PM, Graves EJ, Godena VK, Marrone L, Bhargava A, Ray S, Ning K, Crane H, Hautbergue GM, El-Khamisy SF, Azzouz M. Karyka E, et al. Among authors: marchi pm. Life Sci Alliance. 2022 Apr 19;5(8):e202101145. doi: 10.26508/lsa.202101145. Print 2022 Aug. Life Sci Alliance. 2022. PMID: 35440492 Free PMC article.
131 results